Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis

Authors

  • Natalia Fulle IPEN/USP
  • Gaianê Sabundjian

DOI:

https://doi.org/10.15392/2319-0612.2022.2007

Keywords:

prostate cancer, diagnosis, Positron Emission Tomography ,18F-FDG, 68Ga-PSMA-11.

Abstract

Prostate cancer is the second most incident neoplasm in men, except for non-melanoma skin cancer, and has the second highest mortality rate in Brazil. Early diagnosis increases the chances of cure and enables a less aggressive treatment for the patient. Nuclear Medicine presents effective alternatives for prostate cancer diagnosis, such as Positron Emission Tomography (PET) or PET and Computed Tomography (PET/CT) imaging.  The aim of this study is to compare the advantages and disadvantages of the radiopharmaceuticals 18F-FDG and 68Ga-PSMA-11 used for PET or PET/CT in the diagnosis of this type of cancer. Compared to 18F-FDG, 68Ga-PSMA-11 has some advantages such as its availability by means of generators, the independent production of a cyclotron facility and its theranostic potential. The disadvantages compared to 18F-FDG are the scalability of 18F-FDG production compared to limited generator production.  Despite its favorable characteristics, the radiopharmaceutical 18F-FDG has limitations in the diagnosis of some types of tumors, such as prostate cancer. All the favorable and unfavorable aspects of these two radiopharmaceuticals are presented in this work.

Downloads

Download data is not yet available.

References

CAO, Wei et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Medical Journal, v. 134, n. 7, p. 783, 2021. DOI: https://doi.org/10.1097/CM9.0000000000001474

SARACCI, R.; WILD, C. P. International Agency for Research on Cancer - The First 50. Lyon: IARC, 2015. Available at:<http://www.iarc.fr/en/publications/books/iarc50/IARC_50%20years.p

df >. Last accessed: 16 jul. 2021.

SUNG, Hyuna et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, v.71, n. 3, p. 209-249, 2021. DOI: https://doi.org/10.3322/caac.21660

SIEGEL, REBECCA L. et al. Cancer Statistics, 2021. CA: a Cancer Journal for Clinicians, v. 71, n. 1, p. 7-33, 2021. DOI: https://doi.org/10.3322/caac.21654

INSTITUTO NACIONAL DE CÂNCER, 2020. Estimativa 2020. Available at <https://www.inca.gov.br/estimativa/introducao>. Last accessed: 25 mar. 2021.

MINISTÉRIO DA SAÚDE. Secretaria de atenção à saúde. Departamento de ações programáticas estratégicas. Área técnica de saúde do homem. Política nacional de atenção integral à saúde do homem: princípios e diretrizes. Brasília: Ministério da Saúde, 92 p; 2009.

PESQUISA DO INSTITUTO ONCOGUIA. Conhecendo a realidade dos pacientes com câncer de próstata, 2015.

KESCH C, KRATOCHWIL C, MIER W, KOPKA K, GIESEL FL. 68Ga or 18F for prostate cancer imaging? Journal of Nuclear Medicine, v. 58, n. 5, p. 687-688, 2017. DOI: https://doi.org/10.2967/jnumed.117.190157

ALMUHAIDEB, Ahmad; PAPATHANASIOU, Nikolaos; BOMANJI, Jamshed. 18F-FDG PET/CT imaging in oncology. Annals of Saudi medicine, v. 31, n. 1, p. 3-13, 2011. DOI: https://doi.org/10.4103/0256-4947.75771

RUDROFF, Thorsten; KINDRED, John H.; KALLIOKOSKI, Kari K. [18F]-FDG positron emission tomography—an established clinical tool opening a new window into exercise physiology. Journal of Applied Physiology, v. 118, n. 10, p. 1181-1190, 2015. DOI: https://doi.org/10.1152/japplphysiol.01070.2014

MORRIS, Michael J. et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology, v. 59, n. 6, p. 913-918, 2002. DOI: https://doi.org/10.1016/S0090-4295(02)01509-1

SANZ, G. et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU international, v. 84, n. 9, p. 1028-1031, 1999. DOI: https://doi.org/10.1046/j.1464-410x.1999.00349.x

SUNG, J. et al. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU international, v. 92, n. 1, p. 24-27, 2003. DOI: https://doi.org/10.1046/j.1464-410X.2003.04297.x

HILLNER, Bruce E. et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. Journal of Nuclear Medicine, v. 49, n. 12, p. 1928-1935, 2008. DOI: https://doi.org/10.2967/jnumed.108.056713

JACOBSON, Orit; KIESEWETTER, Dale O.; CHEN, Xiaoyuan. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjugate chemistry, v. 26, n. 1, p. 1-18, 2015. DOI: https://doi.org/10.1021/bc500475e

CALAIS, Jeremie et al. Impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. Journal of Nuclear Medicine, v. 59, n. 3, p. 434-441, 2018.

SONNI, Ida et al. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings : a prospective single-center study. Journal of Nuclear Medicine, v. 61, n. 8, p. 1153-1160, 2020. DOI: https://doi.org/10.2967/jnumed.119.237602

ALBISINNI, Simone et al. Clinical impact of 68Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate‐specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU international, v. 120, n. 2, p. 197-203, 2017. DOI: https://doi.org/10.1111/bju.13739

KUTEN, Jonathan et al. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. Journal of Nuclear Medicine, v. 61, n. 4, p. 527-532, 2020. DOI: https://doi.org/10.2967/jnumed.119.234187

RAUSCHER, Isabel et al. 68 Ga-PSMA ligand PET/CT in patients with prostate cancer : How we review and report. Cancer Imaging, v. 16, n. 1, p. 1- 10, 2016 DOI: https://doi.org/10.1186/s40644-016-0072-6

Downloads

Published

2022-12-04

How to Cite

Fulle, N., & Sabundjian, G. (2022). Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis . Brazilian Journal of Radiation Sciences, 10(3B (Suppl.). https://doi.org/10.15392/2319-0612.2022.2007

Issue

Section

INAC 2021_XV ENAN